CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 114 enrolled
Drug / intervention
Epsilon-aminocaproic acid administered +1 moredrug
Likely dose
Tranexamic acid 30 mg/kg IV bolus followed by 16 mg/kg/hr maintenance infusion, or Epsilon-aminocaproic acid 150 mg/kg IV bolus followed by 15 mg/kg/hr maintenance infusionAI-extracted
Key inclusion· 1
  • Scheduled for cardiac surgery requiring cardiopulmonary bypass
Key exclusion· 10
  • History of stroke or non-coronary thrombotic disorders (DVT, PE)
  • Clinical signs of non-coronary thrombotic disease
  • Known congenital deficiencies: Protein C, Protein S, Antithrombin, or homozygous Factor V Leiden
  • Known congenital bleeding disorders

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02655653
NCT02655653Phase 3Completed

A Randomized, Double-blinded Trial Comparing the Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery

Montefiore Medical Center·interventional·Posted Jan 14, 2016·Updated Jun 16, 2020

In Brief

A Phase 3 clinical trial evaluating Epsilon-aminocaproic acid administered and Tranexamic Acid administered for Bleeding. Completed, enrolled 114 participants.

Detailed Summary

The investigators primary objective is to compare the effectiveness of epsilon-aminocaproic acid (EACA) and tranexamic acid (TA) in reducing bleeding and transfusion in cardiac surgery, with the hypothesis that TA is more effective. The investigators also seek to further examine the clinical benefits and adverse effects profiles of epsilon-aminocaproic acid and tranexamic acid.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBleeding
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 14, 2016
Enrollment StartOct 1, 2008
Primary CompletionOct 1, 2010
Study CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 10.5 years ago

Interventions

Epsilon-aminocaproic acid administereddrug

Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.

Tranexamic Acid administereddrug

Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.